- Healthcare Professionals
- Research
- Clinical trials
- Mcl study
Cancer
Cancer
2022-06-16T00:00:00.000+08:00
Ongoing
MCL study
MCL study
Mantle Cell Lymphoma
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Trial overview
Description
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress
Study details
For detailed information on this trial, please click here
Trial status
Actively recruiting
Priniciple Investigator

